• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

Liraglutide associated with lower incidence of death from CV causes in type 2 diabetics

byDavid ArsaniousandShaidah Deghan, MSc. MD
May 11, 2022
in General Medicine Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Patients with type 2 diabetes who received liraglutide were observed to have a significantly lower incidence of the composite of death from cardiovascular causes, nonfatal MI, and nonfatal stroke, versus patients who received placebo.

2. The rates of both all-cause mortality and nephropathy were significantly lower for patients who received liraglutide than for patients who received placebo.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Liraglutide is a glucagon-like peptide 1 (GLP-1) analogue, approved for the treatment of type 2 diabetes mellitus (T2DM). While the microvascular benefits of this drug are well characterized through its effect on improving glycemic control, its macrovascular effects are less than certain at this point.

In this multicenter, double-blind, placebo-controlled trial, patients were randomized in a 1:1 ratio to receive a once daily liraglutide or placebo subcutaneous injection. The primary outcome in the study was the first occurrence of death from cardiovascular causes, nonfatal MI, or nonfatal stroke. The primary outcome was found to be significantly lower in the liraglutide group than in the placebo group. Additionally, death from CV causes alone was also found to be significantly lower in the liraglutide group than in the placebo group. All-cause mortality was also found to be significantly lower in the liraglutide group than in the placebo group, as well.

This study draws strength from strict inclusion and exclusion criteria that made patients, effectively, treatment naïve at baseline: T2DM patients with HbA1c >7.0% who had not received any medication for this condition previously. Its impact, however, is somewhat limited by the modest follow-up period of 42-60 months.

Click to read the study, published today in NEJM

RELATED REPORTS

Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events

Systematic review and meta-analysis of statin-induced reduction in LDL-C demonstrates modest absolute benefits

Low- and no-calorie sweetened beverages associated with reduced body weight compared to sugar-sweetened beverages: a systematic review and meta-analysis

Relevant Reading: Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

In-Depth [randomized controlled trial]: This study was a multicenter, double-blind, placebo-controlled trial, that included a total of 9340 patients. The patients were randomized in a 1:1 ratio to receive a once daily liraglutide or placebo subcutaneous injection. The mean follow-up was 3.8 years. The primary composite outcome (first occurrence of death from cardiovascular causes, nonfatal MI, or nonfatal stroke) occurred in fewer patients in the liraglutide group 13.0% than in the placebo group 14.9% (HR 0.87; 95%CI 0.78 to 0.97; p < 0.001 for non-inferiority; p = 0.01 for superiority). Death from CV causes was significantly lower in the liraglutide group 4.7% than in the placebo group 6.0% (HR 0.78; 95%CI 0.66 to 0.93; p = 0.007). The rate of all-cause mortality was also significantly lower in the liraglutide group 8.2% than in the placebo group 9.6% (HR 0.85; 95%CI 0.74 to 0.97; p = 0.02). The rate of nephropathy was significantly lower in the liraglutide group than in the placebo group (1.5 vs 1.9 events per hundred patient-years; HR 0.78; 95%CI 0.67 to 0.92; p = 0.003).

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascular riskdiabetes mellitusliraglutide
Previous Post

Empagliflozin reduces the risk of long-term renal effects in type 2 diabetes

Next Post

Point-of-care hemostatic test during TAVR procedure may help predict negative outcomes

RelatedReports

FDA-approved weight loss medications associated with weight loss at one year
Cardiology

Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events

May 25, 2022
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Cardiology

Systematic review and meta-analysis of statin-induced reduction in LDL-C demonstrates modest absolute benefits

April 7, 2022
Added sugar intake associated with mortality from cardiovascular disease
Cardiology

Low- and no-calorie sweetened beverages associated with reduced body weight compared to sugar-sweetened beverages: a systematic review and meta-analysis

March 16, 2022
Blindness and visual impairment decreasing worldwide
Chronic Disease

Faricimab may improve visual acuity in patients with diabetic macular edema

March 8, 2022
Next Post
Image-guided percutaneous drainage of pericardial effusions is safe and effective

Point-of-care hemostatic test during TAVR procedure may help predict negative outcomes

Increased complications associated with emergent repeat cesarean

Later physician rounding improves satisfaction of postpartum women

Significant healthcare disparities exist between rural and non-rural children

Childhood epilepsy linked to increased comorbidity

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.